Mechanisms of acquired resistance to c-Src kinase inhibitor in triple negative breast cancer

被引：0
|
作者：
Gilani, Rabia A.
Lachacz, Eric J.
Phadke, Sameer
Bao, Li Wei
Cheng, Xu
Jiagge, Evelyn M.
Soellner, Matthew B.
Merajver, Sofia D.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4117
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Metabolic regulation and drug resistance in c-Src activated triple negative breast cancer
    Jung, K. H.
    Park, J. H.
    Sirupangi, T.
    Jia, D.
    Gandhi, N.
    Pudakalakatti, S.
    Elswood, J.
    Porter, W.
    Putluri, N.
    Zhang, X. H-F
    Chen, X.
    Bhattacharya, P. K.
    Creighton, C. J.
    Lewis, M. T.
    Rosen, J. M.
    Wong, L-J C.
    Das, G. M.
    Osborne, C. K.
    Rimawi, M. F.
    Kaipparettu, B. A.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [2] Constitutive Activation of Src Kinase as a Mechanism of Acquired Resistance to Dasatinib in Triple Negative Breast Cancer
    Corkery, B.
    Crown, J.
    Roche, S.
    O'Connor, R.
    Tryfanopoulos, D.
    Clynes, M.
    O'Donovan, N.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 787S - 787S
  • [3] Autophagy-mediated survival mechanism to c-Src inhibitor therapy in triple negative breast cancer
    Jung, Kwanghwa
    Park, Junhyoung
    Sirupangi, Tirupataiah
    Jia, Dongya
    Gandhi, Nishant
    Pudakalakatti, Shivanand
    Elswood, Jessica
    Porter, Weston
    Putluri, Nagireddy
    Zhang, Xiang H. -F
    Chen, Xi
    Bhattacharya, Pratip K.
    Creighton, Chad J.
    Lewis, Michael T.
    Rosen, Jeffrey M.
    Wong, Lee-Jun C.
    Das, Gokul M.
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Kaipparettu, Benny Abraham
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [4] c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin invitro and invivo
    Lou, Longquan
    Yu, Ziyi
    Wang, Yue
    Wang, Shui
    Zhao, Yi
    [J]. CANCER SCIENCE, 2018, 109 (05): : 1648 - 1659
  • [5] C-src: A potential target for the treatment of triple-negative breast cancer.
    Walsh, S.
    Tryfonopoulos, D.
    Quinn, C.
    Flanagan, L.
    Pierce, A.
    McDermott, E.
    Evoy, D.
    O'Donovan, N.
    Crown, J.
    Duffy, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Phosphorylated c-Src predicts clinical outcome in triple negative breast cancers
    Elsberger, B.
    Tovey, S. M.
    Tan, B. A.
    Brown, S. B. F.
    Brunton, V. G.
    Mallon, E. A.
    Cooke, T. G.
    Edwards, J.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 179S - 179S
  • [7] The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
    Egeland, Eivind Valen
    Seip, Kotryna
    Skourti, Eleni
    Oy, Geir Frode
    Pettersen, Solveig J.
    Pandya, Abhilash D.
    Dahle, Maria A.
    Haugen, Mads H.
    Kristian, Alexander
    Nakken, Sigve
    Engebraaten, Olav
    Maelandsmo, Gunhild M.
    Prasmickaite, Lina
    [J]. BRITISH JOURNAL OF CANCER, 2024,
  • [8] Development of a Highly Selective c-Src Kinase Inhibitor
    Brandvold, Kristoffer R.
    Steffey, Michael E.
    Fox, Christel C.
    Soellner, Matthew B.
    [J]. ACS CHEMICAL BIOLOGY, 2012, 7 (08) : 1393 - 1398
  • [9] Development of a Chimeric c-Src Kinase and HDAC Inhibitor
    Ko, Kristin S.
    Steffey, Michael E.
    Brandvold, Kristoffer R.
    Soellner, Matthew B.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (08): : 779 - 783
  • [10] Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer
    Lefebvre, Cory
    Litchfield, David
    Allan, Alison
    [J]. CANCER RESEARCH, 2019, 79 (13)
12345